Genocea Biosciences Inc (OTCPK:GNCAQ)

$ 0.0001 0 (0%) Market Cap: - Enterprise Value: -4.65 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Genocea Biosciences Inc at Needham Healthcare Conference Transcript
Apr 12, 2022
Genocea Biosciences Inc at American Association for Cancer Research (AACR) Investor Webinar Transcript
Apr 08, 2022
Q4 2021 Genocea Biosciences Inc Earnings Call Transcript
Mar 10, 2022

$1.17 (-1.68%)

Earnings
Q3 2021 Genocea Biosciences Inc Earnings Call Transcript
Oct 28, 2021

$1.8 (+7.78%)

Earnings
Q2 2021 Genocea Biosciences Inc Earnings Call Transcript
Jul 29, 2021

$2.04 (+0.49%)

Earnings
Q1 2021 Genocea Biosciences Inc Earnings Call Transcript
Apr 29, 2021

$2.66 (+2.31%)

Earnings
Q4 2020 Genocea Biosciences Inc Earnings Call Transcript
Feb 11, 2021

$3.28 (-2.96%)

Earnings
Genocea Biosciences, Inc. - Special Call Transcript
Nov 09, 2020
Q3 2020 Genocea Biosciences Inc Earnings Call Transcript
Oct 29, 2020

$2.12 (-6.61%)

Earnings
Q2 2020 Genocea Biosciences Inc Earnings Call Transcript
Jul 23, 2020

$3.6 (+14.65%)

Earnings
Genocea Biosciences Inc Annual Shareholders Meeting Transcript
Jun 01, 2020
Genocea Biosciences, Inc. - Shareholder/Analyst Call Transcript
May 12, 2020
Q1 2020 Genocea Biosciences Inc Earnings Call Transcript
Apr 30, 2020

$2.28 (+1.33%)

Earnings
Q4 2019 Genocea Biosciences Inc Earnings Call Transcript
Feb 13, 2020

$2.18 (-3.33%)

Earnings
Q3 2019 Genocea Biosciences Inc Earnings Call Transcript
Oct 24, 2019

$2.45 (-6.49%)

Earnings
Q2 2019 Genocea Biosciences Inc Earnings Call Transcript
Jul 25, 2019

$3.53 (-7.11%)

Earnings
Genocea Biosciences, Inc. - Special Call Transcript
Jun 03, 2019
Q1 2019 Genocea Biosciences Inc Earnings Call Transcript
Apr 30, 2019

$5.6 (-7.89%)

Earnings
Q4 2018 Genocea Biosciences Inc Earnings Call Transcript
Feb 28, 2019

$5.84 (-18.89%)

Earnings

Genocea Biosciences, Inc. - Shareholder/Analyst Call Transcript

May 12, 2020 / 04:00PM GMT

Release Date Price: $2.7 (+10.66%)

Transcript

Operator

Good day, and welcome to the Genocea Virtual KOL Symposium on GEN-011 on Transforming T Cell Therapy for Solid Tumors. Today's conference is being recorded. I'll now turn the call over to Chip Clark, CEO of Genocea. Please go ahead, sir.

William D. Clark

Genocea Biosciences, Inc. - President, CEO & Director

Good morning, everyone. Thank you for joining us. Let me first express the hope that everybody in the audience is safe and well. Let me also express my gratitude for and pride with all of the Genoceans that we are here to represent today. When I think that it was just 18 months ago, or even less, that we decided to start a neoantigen cell therapy program and to be here today on the cusp of filing an IND with what we think is a potential best-in-class program is just really exciting.

So I will ask you, with that said, to heed this disclaimer because the Genoceans today will be making some forward-looking statements. After my brief introduction, I will turn things over to Dr. Eric Tran. Eric comes -- is a member of the Genocea SAB. He worked in

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.